These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance. Chung Y; Lee SH; Kim DH; Kang CY J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078 [TBL] [Abstract][Full Text] [Related]
4. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Zhang X; Reddy J; Ochi H; Frenkel D; Kuchroo VK; Weiner HL Int Immunol; 2006 Apr; 18(4):495-503. PubMed ID: 16540527 [TBL] [Abstract][Full Text] [Related]
5. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470 [TBL] [Abstract][Full Text] [Related]
6. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Belghith M; Bluestone JA; Barriot S; Mégret J; Bach JF; Chatenoud L Nat Med; 2003 Sep; 9(9):1202-8. PubMed ID: 12937416 [TBL] [Abstract][Full Text] [Related]
7. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Chatenoud L Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225 [TBL] [Abstract][Full Text] [Related]
8. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382 [TBL] [Abstract][Full Text] [Related]
9. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Perruche S; Zhang P; Liu Y; Saas P; Bluestone JA; Chen W Nat Med; 2008 May; 14(5):528-35. PubMed ID: 18438416 [TBL] [Abstract][Full Text] [Related]
10. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. Ochi H; Abraham M; Ishikawa H; Frenkel D; Yang K; Basso A; Wu H; Chen ML; Gandhi R; Miller A; Maron R; Weiner HL J Neurol Sci; 2008 Nov; 274(1-2):9-12. PubMed ID: 18804221 [TBL] [Abstract][Full Text] [Related]
12. Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies. Montero E; Nussbaum G; Kaye JF; Perez R; Lage A; Ben-Nun A; Cohen IR J Autoimmun; 2004 Aug; 23(1):1-7. PubMed ID: 15236747 [TBL] [Abstract][Full Text] [Related]
13. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells. George Chandy A; Hultkrantz S; Raghavan S; Czerkinsky C; Lebens M; Telemo E; Holmgren J Immunology; 2006 Jul; 118(3):311-20. PubMed ID: 16827892 [TBL] [Abstract][Full Text] [Related]
14. In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Jiang S; Golshayan D; Tsang J; Lombardi G; Lechler RI Int Immunopharmacol; 2006 Dec; 6(13-14):1879-82. PubMed ID: 17161340 [TBL] [Abstract][Full Text] [Related]
15. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173 [TBL] [Abstract][Full Text] [Related]
16. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity. Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341 [TBL] [Abstract][Full Text] [Related]
17. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Wei WZ; Jacob JB; Zielinski JF; Flynn JC; Shim KD; Alsharabi G; Giraldo AA; Kong YC Cancer Res; 2005 Sep; 65(18):8471-8. PubMed ID: 16166327 [TBL] [Abstract][Full Text] [Related]
18. CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'. Rojo JM; Pini E; Ojeda G; Bello R; Dong C; Flavell RA; Dianzani U; Portolés P Int Immunol; 2008 Apr; 20(4):577-89. PubMed ID: 18310064 [TBL] [Abstract][Full Text] [Related]
19. CD3-specific antibody-induced active tolerance: from bench to bedside. Chatenoud L Nat Rev Immunol; 2003 Feb; 3(2):123-32. PubMed ID: 12563296 [TBL] [Abstract][Full Text] [Related]
20. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. Meiron M; Zohar Y; Anunu R; Wildbaum G; Karin N J Exp Med; 2008 Oct; 205(11):2643-55. PubMed ID: 18852294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]